Colonoscopy findings after increasing two-stool faecal immunochemical test (FIT) cut-off: Cross-sectional analysis of the SCREESCO randomized trial
- PMID: 38845164
- DOI: 10.1111/joim.13810
Colonoscopy findings after increasing two-stool faecal immunochemical test (FIT) cut-off: Cross-sectional analysis of the SCREESCO randomized trial
Abstract
Background: We determined the impact of an increased two-stool faecal immunochemical test (FIT) cut-off on colonoscopy positivity and relative sensitivity and specificity in the randomized controlled screening trial screening of Swedish colons conducted in Sweden.
Methods: We performed a cross-sectional analysis of participants in the FIT arm that performed FIT between March 2014 and 2020 within the study registered with ClinicalTrials.gov, NCT02078804, who had a faecal haemoglobin concentration of at least 10 µg/g in at least one of two stool samples and who underwent a colonoscopy (n = 3841). For each increase in cut-off, we computed the positive predictive value (PPV), numbers needed to scope (NNS), sensitivity and specificity for finding colorectal cancer (CRC) and advanced neoplasia (AN; advanced adenoma or CRC) relative to cut-off 10 µg/g.
Results: The PPV for AN increased from 23.0% (95% confidence intervals [CI]: 22.3%-23.6%) at cut-off 10 µg/g to 28.8% (95% CI: 27.8%-29.7%) and 33.1% (95% CI: 31.9%-34.4%) at cut-offs 20 and 40 µg/g, respectively, whereas the NNS to find a CRC correspondingly decreased from 41 to 27 and 19. The PPV for AN was higher in men than women at each cut-off, for example 31.5% (95% CI: 30.1%-32.8%) in men and 25.6% (95% CI: 24.3%-27.0%) in women at 20 µg/g. The relative sensitivity and relative specificity were similar in men and women at each cut-off.
Conclusion: A low cut-off of around 20-40 µg/g allows detection and removal of many AN compared to 10 µg/g while reducing the number of colonoscopies in both men and women.
Keywords: colonoscopy; colorectal cancer; faecal immunochemical test; screening.
© 2024 The Author(s). Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
Comment in
-
Making the best use of quantitative fecal immunochemical test results in colorectal cancer screening.J Intern Med. 2024 Aug;296(2):118-120. doi: 10.1111/joim.13812. Epub 2024 Jun 18. J Intern Med. 2024. PMID: 38894589 No abstract available.
Similar articles
-
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD009276. doi: 10.1002/14651858.CD009276.pub2. Cochrane Database Syst Rev. 2022. PMID: 35665911 Free PMC article.
-
The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.BMC Cancer. 2022 Dec 12;22(1):1299. doi: 10.1186/s12885-022-10372-2. BMC Cancer. 2022. PMID: 36503495 Free PMC article.
-
Endoscopist adenoma detection rate associated with neoplasia detection during subsequent-round colonoscopy in fecal immunochemical test-based colorectal cancer screening: cross-sectional analysis of the SCREESCO randomized controlled trial.Gastrointest Endosc. 2025 Sep;102(3):391-399. doi: 10.1016/j.gie.2025.01.037. Epub 2025 Feb 4. Gastrointest Endosc. 2025. PMID: 39914632 Clinical Trial.
-
Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.Health Technol Assess. 2017 May;21(33):1-234. doi: 10.3310/hta21330. Health Technol Assess. 2017. PMID: 28643629 Free PMC article.
-
Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening.N Engl J Med. 2024 Mar 14;390(11):984-993. doi: 10.1056/NEJMoa2310336. N Engl J Med. 2024. PMID: 38477986
References
-
- Njor SH, Andersen B, Friis‐Hansen L, de Haas N, Linnemann D, Nørgaard H, et al. The optimal cut‐off value in fit‐based colorectal cancer screening: an observational study. Cancer Med. 2021;10:1872–1879.
-
- van der Meulen MP, Lansdorp‐Vogelaar I, van Heijningen EM, Kuipers EJ, van Ballegooijen M. Nonbleeding adenomas: evidence of systematic false‐negative fecal immunochemical test results and their implications for screening effectiveness‐a modeling study. Cancer. 2016;122:1680–1688.
-
- Berry E, Miller S, Koch M, Balasubramanian B, Argenbright K, Gupta S. Lower abnormal fecal immunochemical test cut‐off values improve detection of colorectal cancer in system‐level screens. Clin Gastroenterol Hepatol. 2020;18:647–653.
-
- Breekveldt EC, Toes‐Zoutendijk E, de Jonge L, Spaander MCW, Dekker E, van Kemenade FJ, et al. Personalized colorectal cancer screening: study protocol of a mixed‐methods study on the effectiveness of tailored intervals based on prior f‐Hb concentration in a fit‐based colorectal cancer screening program (PERFECT‐FIT). BMC Gastroenterol. 2023;23:1–10.
-
- Brenner H, Werner S. Selecting a cut‐off for colorectal cancer screening with a fecal immunochemical test. Clin Transl Gastroenterol. 2017;8:e111.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical